<DOC>
	<DOCNO>NCT01872936</DOCNO>
	<brief_summary>The purpose open-label study ass safety , tolerability , antiviral activity , genotype resistance associate virological failure , pharmacokinetics pharmacodynamics two dose regimen miravirsen combination telaprevir ribavirin subject hepatitis C virus genotype 1 infection null responder pegylated-interferon alpha ribavirin .</brief_summary>
	<brief_title>Miravirsen Combination With Telaprevir Ribavirin Null Responder Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Diagnosis chronic hepatitis C genotype 1 infection BMI 18 38 kg/m2 Null responder pegylated interferon alpha ribavirin Coinfection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Significant liver disease addition hepatitis C Decompensated liver disease medical history current clinical feature Histologic evidence hepatic cirrhosis Concurrent clinically significant medical diagnosis ( CHC ) Concurrent social condition ( e.g . drug abuse , alcohol excess , poor live accommodation ) Clinically significant illness within 30 day precede entry study Participated investigational drug study within 30 day 5 halflives , whichever longer , prior start study medication History clinically significant allergic drug reaction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>